2024-515442-17-00RecruitingPhase 1
Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone or in combination with itraconazole in male and female healthy adults
Chiesi Farmaceutici S.p.A.1 site in 1 country132 target enrollmentStarted: November 6, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Enrollment
- 132
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
GLOBAL CLINICAL DEVELOPMENT
Scientific
Chiesi Farmaceutici S.p.A.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Evaluate the safety, side effects and maximum tolerable dose of 5 Antimicrobial Peptides on the skin of healthy volunteers to the treatment of Skin and Soft Tissue Infections.IRCT20190924044863N1Mashhad University of Medical Sciences30
Completed
Not Applicable
The evaluation of the clinical effect and safety of stereotactic body radiationtherapy for hepatocellularcarcinomaJPRN-UMIN000016834Hiroshima university100
Recruiting
Not Applicable
Safety evaluation and therapeutic effect analysis of knee hyperthermia with resonant cavity applicatorJPRN-UMIN000033721nternational University of Health and Welfare20
Completed
Not Applicable
Clinical Evaluation of the Safety and Effectiveness of Harvest Autologous Platelet Concentrate and Harvest Autologous Thrombin for Treatment of Lower Extremity Chronic Diabetic UlcersISRCTN28965380Harvest Technologies Corp. (USA)59
Active, not recruiting
Phase 1
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12